Clinical trials: Sexually Transmitted Infections (STIs)
HIV, AIDS
EuroSIDA As An External Comparator To MOTIVATE Trials
Human Immunodeficiency Virus (HIV) infected patients who meet the entry criteria for the maraviroc pivotal trials (Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients, MOTIVATE) will be…
- Trial name
- NCT01329783
- Testing
- maraviroc
- Volunteers
- 1,181 people
- Sponsor
- ViiV Healthcare
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety and immunogenicity of Cervarix in HIV infected…
- Trial name
- NCT01031069
- Testing
- GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
- Where
- 15 sites in Brazil, Estonia and 2 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sarcoma, Kaposi, HIV Infections
A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma
To determine the safety and tolerance of interleukin-4 (IL-4) in patients with AIDS-related Kaposi's sarcoma. To determine the effects of IL-4 on tumor growth in patients with AIDS-related Kaposi's sarcoma.
- Trial name
- NCT00000769
- Testing
- Interleukin-4
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Positive
Oligonucleotide Ligation Assay (OLA) Resistance Study
The investigators propose to gauge improvements in the rate of durable suppression of viral replication by ART when OLA is used to guide clinical decisions at the PEPFAR Coptic Hope Center in Kenya, and to determine the…
- Trial name
- OLA (NCT01898754)
- Testing
- Pre-ART Oligonucleotide Assay (OLA)
- Where
- 2 sites in Kenya
- Volunteers
- 991 people
- Sponsor
- University of Washington
HIV Infections
A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy
To evaluate and compare the effectiveness and toxicity associated with didanosine ( ddI ) and zalcitabine ( dideoxycytidine; ddC ) in patients with HIV infection who are intolerant of or have failed zidovudine ( AZT ) therapy.
- Trial name
- NCT00000969
- Testing
- Zalcitabine, Didanosine
- Where
- 16 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)
Safety and efficacy are key issues in antiretroviral therapy (ART) selection. Efavirenz (EFV) is an important component of combination ART in treatment naive individuals.
- Trial name
- NCT01271894
- Testing
- Efavirenz
- Where
- 4 sites in Argentina, South Africa and 2 more
- Volunteers
- 40 people
- Sponsor
- Kirby Institute
Gonorrhea
Zoliflodacin in Uncomplicated Gonorrhoea
This trial is a multi-center, open label, randomized controlled, non-inferiority phase III trial evaluating the safety and efficacy of a 3 g oral dose of zoliflodacin compared to a combination of a single intra-muscular 500 mg…
- Trial name
- NCT03959527
- Testing
- zoliflodacin, ceftriaxone, azithromycin
- Where
- 17 sites in United States, Belgium and 3 more
- Volunteers
- 1,011 people
- Sponsor
- Global Antibiotics Research and Development Partnership
Sexually Transmitted Diseases, Substance-Related Disorders
Partner-Specific HIV Risk Reduction Intervention for Drug-Using Adolescents
The purpose of this study is to develop and pilot test a partner-specific HIV risk reduction intervention for currently or recently incarcerated adolescents who report problematic substance use.
- Trial name
- GET UP (NCT00831883)
- Testing
- Partner-Specific IMB-based HIV risk reduction intervention, Healthy Lifestyle
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Hiv
Efficacy Trial of Life Simulation Game to Routinize Adolescent HIV Testing
This study will aim to assess the acceptability, usability and efficacy of using state-of-the-art video game technology to increase HIV testing among adolescents and young adults (AYA) ages 13-24.
- Trial name
- NCT04917575
- Testing
- Mobile Game, Mobile Application
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- George Washington University
Papillomavirus Infections
GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)
This study will collect safety information on the use of GARDASIL™ in the Philippines.
- Trial name
- NCT01355003
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women
The purpose of this phase IIB MedImmune-sponsored study was to evaluate the efficacy of the HPV-16/18 VLP vaccine in the prevention of infection with HPV-16 and/or HPV-18 in adolescent and young adult women.
- Trial name
- NCT00689741
- Testing
- Cervarix
- Volunteers
- 1,113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infection
Pilot Study of Raltegravir Lipodystrophy IISP
The substitution of raltegravir for the NRTIs will result in some reversal of the long term adverse effect of lipodystrophy (specifically peripheral lipoatrophy) that is associated with the chronic use of NRTIs.
- Trial name
- NCT01164605
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Southern California Institute for Research and Education
HIV Infections
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
To determine the proportion of patients treated with amprenavir, zidovudine (ZDV), stavudine (D4T) and lamivudine (3TC) whose HIV-1 RNA level remains below the level of detection during 96 weeks of therapy.
- Trial name
- NCT00001095
- Testing
- Indinavir sulfate, Amprenavir, Nevirapine
- Where
- 12 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)
This multicenter, open-label, noncomparative study evaluates two oral formulations of raltegravir (MK-0518, film-coated tablet and chewable tablet) in combination with other antiretroviral agents for safety, tolerability, and…
- Trial name
- NCT01717287
- Testing
- Raltegravir Film-coated Tablet, Raltegravir Chewable Tablet, Other Anti-Retroviral Therapy
- Volunteers
- 32 people
- Sponsor
- Merck Sharp & Dohme LLC
Sarcoma, Kaposi, HIV Infections
Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma
To determine the safety and effectiveness of combining zidovudine (AZT) and interferon alfa-2a (IFN-A2a) in a treatment for Kaposi's sarcoma (KS) in patients who have AIDS.
- Trial name
- NCT00000687
- Testing
- Interferon alfa-2a, Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis, Cryptococcal, HIV Infections
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B
To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal meningitis in patients who have had an unsatisfactory response to or have experienced unacceptable toxicity with amphotericin B.
- Trial name
- NCT00002306
- Testing
- Fluconazole
- Where
- 14 sites in United States
- Sponsor
- Pfizer
HIV-1-infection
Dolutegravir in Real Life in Lesotho
DO-REAL is an observational cohort study assessing the large-scale roll-out of the antiretroviral drug dolutegravir (DTG) in Lesotho.
- Trial name
- DO-REAL (NCT04238767)
- Testing
- Dolutegravir
- Where
- 2 sites in Lesotho
- Volunteers
- 1,433 people
- Sponsor
- Swiss Tropical & Public Health Institute
HPV Infection
Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)
This study is a multi-country and multi-site project to estimate the point-prevalence of high-risk (HR) HPV genotype infections among representative samples of girls and women aged 9-50 years, and among specific sub-populations…
- Trial name
- HPV (NCT06129253)
- Testing
- Urine Sample Collection, Self-collected Vaginal Swab, Blood Samples
- Where
- 8 sites in Bangladesh, Democratic Republic of the Congo and 6 more
- Volunteers
- 29,750 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
HIV Infection, AIDS
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
This is a multi-center study designed to assess the accuracy of Pima™ CD4 Test to enumerate CD4+ T-cells in whole blood over the measurement range expected for the intended population.
- Conditions
- HIV Infection, AIDS, HIV Infections
- Trial name
- NCT00951795
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Abbott RDx Cardiometabolic
Acquired Immunodeficiency Syndrome, HIV Infection
Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist
Patients enrolled in NIH protocol 95-I-0133 at the Clinical Center may participate in an extension phase of this study in which the drug prednisone will be eliminated from the treatment regimen.
- Trial name
- NCT00001475
- Testing
- IL-2 plus Anti-TNF or Thalidomide
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.